Rishabh Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 0.71 M
- Company Age 33 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 85.06%
- Profit Growth 1179.37%
- Ebitda 13.80%
- Net Worth 111.38%
- Total Assets 161.84%
About Rishabh Drugs
Rishabh Drugs Private Limited (RDPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 August 1991 and has a history of 33 years and six months. Its registered office is in New Delhi, Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.71 M, as per Ministry of Corporate Affairs (MCA) records.
Apra Jain, Pradeep Jain, Surender Jain, and Four other members serve as directors at the Company.
Company Details
- Location
New Delhi, Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U33125DL1991PTC045326
- Company No.
045326
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Aug 1991
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Rishabh Drugs?
Board Members (7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Apra Jain  | Director | 03-Oct-1991 | Current |
| Pradeep Jain | Director | 03-Oct-1991 | Current |
| Surender Jain | Director | 03-Oct-1991 | Current |
| Raj Sharma | Director | 03-Oct-1991 | Current |
| Vartika Jain | Director | 02-Aug-2016 | Current |
| Rahul Jain | Director | 02-Aug-2016 | Current |
Financial Performance of Rishabh Drugs.
Rishabh Drugs Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 85.06% increase. The company also saw a substantial improvement in profitability, with a 1179.37% increase in profit. The company's net worth Soared by an impressive increase of 111.38%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rishabh Drugs?
In 2023, Rishabh Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Rajshi Farma Private LimitedApra Jain is a mutual person
- Rajshi Drugs Private Limited
Pradeep Jain, Vartika Jain and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Rishabh Drugs?
Unlock and access historical data on people associated with Rishabh Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rishabh Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rishabh Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
